Phosphoinositide 3-Kinase Γ Inhibitor Ameliorates Concanavalin A-induced Hepatic Injury in Mice

Zhen-ling Wang,Xiao-hua Wu,Li-fang Song,Yong-sheng Wang,Xiao-hong Hu,You-fu Luo,Zhi-zhi Chen,Jin Ke,Xiao-dong Peng,Chun-mei He,Wei Zhang,Li-juan Chen,Yu-qua Wei
DOI: https://doi.org/10.1016/j.bbrc.2009.06.060
IF: 3.1
2009-01-01
Biochemical and Biophysical Research Communications
Abstract:A pivotal role of phosphoinositide 3-kinase-gamma (PI3Kgamma) in inflammatory cell activation and recruitment makes it an attractive target for immunomodulatory therapy. In present study we investigated the therapeutic efficiency of AS605240, a selective PI3Kgamma inhibitor, on hepatitis and liver fibrosis in murine models induced by concanavalin A (ConA). Orally administration of AS605240 significantly improved survival, decreased the serum levels of alanine aminotransaminase (ALT), prevented inflammatory infiltration to liver in ConA-induced hepatitis. TNF-alpha and IFN-gamma at protein levels in serum and mRNA levels in liver were markedly reduced. Downregulated phospho-Akt level of inflammatory cells infiltrating the liver by AS605240 treatment was detected by immunohistochemistry analysis in liver and further confirmed by Western blotting analysis in splenocytes. In ConA-induced chronic liver fibrosis model, accumulation of smooth-muscle actin (SMA)-expressing cells was partially inhibited by AS605240 treatment. These observations suggest that AS605240 might be of therapeutic value for the treatment of ConA-induced hepatic injury.
What problem does this paper attempt to address?